What is HER2+ metastatic breast cancer?

Number One
HER2 tells cells to grow
HER2 is a protein that tells cells to grow. When cells produce too much HER2, they can become cancerous.
Number Two
Tumors form
These cancer cells grow and divide faster than healthy cells, causing tumors to form.
Number Three
Cancer may spread
HER2+ breast cancer can spread to other parts of the body. This is known as HER2+ metastatic breast cancer (or HER2+ mBC).

What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

  • Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
    • for metastatic disease, or
    • have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

How is ENHERTU thought to work?

As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.

ENHERTU is made up
of an antibody with
the chemotherapy attached
The antibody part of
ENHERTU targets and
attaches to HER2 on
the cancer cell
ENHERTU enters
the cancer cell and the
chemotherapy is released
The chemotherapy part
of ENHERTU helps
destroy the cancer cell
as well as other
cells nearby

Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone.

How will I receive ENHERTU?

ENHERTU is given as an intravenous (IV) infusion. You will receive an ENHERTU infusion once every 3 weeks, either at your oncologist’s office or at a nearby infusion center.

Your healthcare provider
will give you medicines
before your infusion to help
prevent nausea and
1st Infusion – 90 minutes
The first ENHERTU infusion
will take about 90 minutes
so the healthcare provider
can monitor any potential
2nd Infusion – 30 minutes
Future ENHERTU infusions
should take about 30 minutes,
if your first infusion was well tolerated

If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Would you like to receive updates
about ENHERTU?

HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.

Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined. Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined. Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined.
Not an actual patient.